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Members of the bone morphogenetic protein (BMP) family have diverse physiological roles. For instance, BMP-2 stimulates
osteogenesis,whileBMP-12inducestheformationoftendon/ligament-liketissues.Here,wedesignedastudytodeterminewhether
BMP-12 has bone and/or cartilage regeneration abilities similar to those of BMP-2. We implanted plasmid vectors encoding either
BMP-2orBMP-12inratswithfemurdefects,andmonitoredthebonehealingprocessfor8-weeks.TheBMP-12transgeneinduced
prominent ﬁbrogenesis by 2 weeks, with bone substitution occurring by 8 weeks. BMP-2, however, was associated predominantly
with osteogenesis throughout the 8 week period. Thus, we conclude that BMP-12 does not function similarly to BMP-2 during
bone healing. Further work is needed to better understand the mechanisms by which it stimulates bony growths to replace the
connective tissues formed during the ﬁrst stages of bone healing.
1.Introduction
Bone morphogenetic proteins (BMPs) are known to be
capable of inducing new bone formation when implanted
subcutaneously in vivo [1]. Within the BMP family, BMP-
2/4 and BMP-7 (OP-1) are especially well known for their
ability to induce bone and cartilage formation, respectively,
byinﬂuencingthediﬀerentiationofmesenchymalprogenitor
cells [2–4].Ontheotherhand,bonemorphogeneticprotein-
12 (BMP-12/GDF-7/CDMP-3) is better known for its ability
to stimulate the formation of tendon/ligament-like tissues
[5]. Many studies, both in vivo and in vitro, have reported
that BMP-12 has the potential to form tendon/ligament-like
tissues [6–10]. However, no research to date has explored
the possible role of this protein on bone or cartilage
regeneration. Further, there has been no direct comparison
betweentheactivityofBMP-12andBMP-2/4/7,todetermine
whether they are equally able to stimulate bone growth,
or whether the activity of BMP-12 is centered solely on
tendon/ligament-like tissues.
If BMP-12 plays a role in both of these processes—
generation of bone as well as connective tissues—it has the
potential to be an invaluable tool for specialists working
with patients who have suﬀeredjoint or periodontal damage.
In these cases, it is common for ligaments and tendons
to be injured as a result of trauma to the bone, since
these structures exist adjacent to each other in the body.
Because the healing process involves regeneration of all these
tissues simultaneously, BMP-12 could oﬀer a unique way to
promote the regrowth of ligaments/tendons, as well as the
bone that is needed to anchor them.
The current study was designed to examine whether
hBMP-12, which is known to induce tendon/ligament
growth, also stimulates bone or cartilage tissue growth
when transferred to a rat bone defect model. Additionally,
we were interested in directly comparing the activity of2 Journal of Tissue Engineering
hBMP-12 to that of hBMP-2. To this end, we studied bone
regeneration among four groups: two groups implanted
with a lyophilized atelocollagen pellet containing a plasmid
vector encoding BMP-12 and BMP-2, respectively, a sham
treatment group receiving only the atelocollagen pellet, and
a control treatment group receiving no pellet at all.
Plasmid vectors are stable molecules and easy to handle
for chemical modulation [11], and plasmid diﬀusion from
the delivery site avoids systemic toxicity due to the high
eﬃciency of DNA turnover in the bloodstream. Together,
these characteristics make plasmid insertion a relatively
safe technique. Previously, plasmid DNA combined with
atelocollagen (a highly puriﬁed type I collagen that has
become one of the most useful scaﬀolds for bone formation)
was transplanted into bone defects in rats and dogs and
succeeded in inducing bone regeneration [2, 12, 13]. Other
collagen-containing formulas—including those containing
the rhBMP2 gene—have been used successfully in in vivo
gene transfer and bone healing [14, 15]. From the results
of this previous work, we expected not only to successfully
transfer the BMP genes, but also to observe the dual
competence of BMP-12 in inducing growth of both soft and
hard tissues. Such a ﬁnding could revolutionize treatments
in the orthopedic and dental ﬁelds, since repairs of joint and
periodontal damage would be improved greatly by a protein
that could facilitate simultaneous regeneration of multiple
types of tissues that comprise these structures.
2.MaterialsandMethods
The protocols for our study were approved by the Recombi-
nant DNA Experiment Committee and the Animal Experi-
ment Committee of our institution. All of the experimental
processes were performed in accordance with institutional
guidelines for the care and manipulation of laboratory
animals.
2.1. Preparation of Implants. Both hBMP-2 and hBMP-12
cDNA were obtained from teeth extracted from patients at
the university hospital. hBMP-2 was cloned from dental pulp
using previously published methods [16], while hBMP-12
cDNA was taken from periodontal ligament scraped oﬀ from
thesurfaceofanextractedtooth(accession#AB158468).The
patients approved of these methods and provided informed
consent before we proceeded with the extractions.
For hBMP-12 cDNA preparation, total RNA of MG63
cells(humanosteosarcoma,JCRB)wasextractedwithIsogen
(Nippon Gene, Japan). Reverse transcription (SuperScript
First-Strand Synthesis System, Invitrogen) and PCR (GC-
RICH PCR SYSTEM, Roche, USA) were performed with
a speciﬁc primer set (forward: 5 -CACGGAGCCCATGGA-
CCTGAGCG-3 ,r e v e r s e :5  -GTGGCCCGCTGCTGCTCA-
TCAG-3 ) constructed using human BAC clone data (acces-
sion #AC012065). The 1439-bp PCR product includes
complete human BMP-12 cds. Ligation of this product into
a vector plasmid, pCRII (Invitrogen, USA), and transforma-
tion of JM109 Escherichia coli cells (TAKARA, Japan) with
the plasmid were performed according to the manufacturer’s
instructions. The ampliﬁed and puriﬁed pCRII plasmids
were digested using EcoRI, after which the isolated insertion
was subcloned in pEGFP-N1 plasmids (Clontech Laborato-
ries Inc., USA). The ﬁnal step was transformation of the
JM109 cells.
Large culture of E. coli clone 2.2 served as the puriﬁed
plasmid encoding the human BMP-12 protein (Figure 1).
cDNA of hBMP-2 was initially located in the BamHI region
of the pBlueBacII plasmid vector multicloning site. This
emerged as pBacBH2, after which the cDNA was inserted
into the BamHI region of the pEGFP-N1 multicloning site.
Then, 100μg of each plasmid vector was prepared separately
in sterile water and mixed with 100μg of 2% bovine
atelocollagen gel (KOKEN Atelocollagen Implant; KOKEN
Co., Tokyo, Japan), which is used clinically as a hemostatic
agent and to heal wounds [17–19]. Finally, 200μl of this
mixture was placed inside the lids of 1.5mL Eppendorf tubes
and lyophilized. The ﬁnal product of this step was used for
implantation of BMP-2 and BMP-12 into the rat models. We
alsopreparedashamimplantofthevehicleplasmid(pEGFP-
N1) only, so that we could gauge the functionality of the
transgene system by assaying for a GFP signal.
2.2. Experimental Design. Ninety-six male Wistar rats, eight
weeks old, were evenly divided into 4 groups. The rats
were anesthetized with a mixture of xylazine, ketamine, and
acepromazine (8, 100, and 2mg/kg, respectively). A round
drill bit was used to create a cortical bone defect (3mm
in diameter) in the anterior surface of the right femoral
metaphysic of each rat (Figure 2). The pellets were then
implanted into the defects; for the two BMP treatment
groups, the implant consisted of atelocollagen harboring the
plasmid vector encoding rhBMP-12 (100μg) or rhBMP-2
(100μg), as appropriate. For the sham group, the implant
was an atelocollagen-only pellet. We also had a control
group,inwhichtheratsreceivednoimplantafterundergoing
surgery to create the bone defect.
At 2, 4, and 8 weeks after the operation, animals were
sacriﬁced (via chloroform inhalation in a draft biohazard
hood), and their femurs were retrieved. Two specimens per
group were used to prepare histological samples, while the
other six were used to conduct real-time PCR (RT-PCR)
analyses to proﬁle expression of bone- and tendon/ligament-
related genes. To conﬁrm successful gene transfer, we ampli-
ﬁed speciﬁc transgene regions after collecting implants from
the sacriﬁced animals. Additionally, we used a confocal laser
scanning microscope (CLSM) (LSM 510, Zeiss) at 488nm
excitation and 509nm emission at the same time point
to detect whether the animal expressed a GFP signal after
receiving a subcutaneous implant of the vehicle pEGFP-N1
plasmid vector.
2.3. Histological Analysis. For the histological study, femurs
were ﬁxed in 10% neutral formalin. The specimens were
decalciﬁed with 10% EDTA; they were then trimmed,
washed, dehydrated with gradients of alcohol, and cleared
in xylene before being embedded in paraﬃn. Longitudinal
sections(5μm)thatincluded thebonedefectswerethenpre-
pared and stained with hematoxylin-and-eosin and Masson’s
trichrome.Journal of Tissue Engineering 3
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Figure 1: A scheme of the expression plasmid vector and the BMP inserts.
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Figure2:Schemeofthefemoraldefectmodel.Adefectinthecortex
at the distal part of the right femur was prepared without irrigating
the marrow.
2.4. Gene Expression. The sites of the bone defects were
resected and homogenized immediately using liquid nitro-
gen. RNA was extracted with an isolation agent (Iso-
gen; Nippon Gene Co., Tokyo, Japan). PCR primers were
designed (Table 1) using sequence data obtained from
GenBank (National Center of Biotechnology Information,
NIH, Bethesda, USA). The chosen mRNAs are known to
be expressed in tendons (Six1), adult connective tissues
including both tendons and ligaments (elastin, decorin,
collagen I, and collagen III), bone or cartilage (aggrecan,
biglycan collagen I, alkaline phosphatase (ALP), and osteo-
calcin), and for housekeeping (glyceraldehyde 3-phosphate
dehydrogenase).
After the ﬁrst strand of cDNA was reverse transcribed
(SuperScript First-Strand Synthesis System for RT-PCR,
Invitrogen), we performed RT-PCR (7300 Real-time PCR
machine,AppliedBiosystems)withSYBRGreenﬂuorescence
dye under an optimal program: 30s at 95◦C ,3 0sa t6 0 ◦C,
and 30s at 72◦C for 40 cycles, followed by a dissociation
step for the second derivatives with a gradient increase
of temperature from 60◦Ct o9 5 ◦C. The identities of the
PCR products were reconﬁrmed using 2% agarose gel
electrophoresis. RT-PCR results were analyzed with relative
quantiﬁcation software. The expression level of each gene is
indicated as the fold change in the number of cDNA copies
relative to the amount of expression in the control group
after normalization with GAPDH.
2.5. Statistical Analysis. Before analyses, the Smirnov-
Grubbs test was used for eliminating outliers from the
dataset. RT-PCR results were analyzed with nonparametric
Kruskal-Wallis tests. Statistical signiﬁcance was deﬁned as
P<. 05.
3. Results
3.1. Translation of the Transgenes. Both hBMP-12
(Figure 3(a)) and hBMP-2 (data not shown) gene
e x p r e s s i o n sw e r ed e t e c t e di nb o n es a m p l e sr e t r i e v e d24 Journal of Tissue Engineering
Table 1: Primer sets for RT-PCR. “Fwd” indicates forward primers and “Rvs” indicates reverse primers. All genes sequences are from the
rat model. Abbreviations are deﬁned as follows: GAPDH: rat glyceraldehyde 3 phosphate dehydrogenase; Col I: rat collagen I; Col III: rat
collagen III; ALP: rat alkaline phosphatase; OCN: rat osteocalcin.
Genes Fwd Rvs Product size (bp)
GAPDH AACTCCCATTCCTCCACCTT GAGGGCCTCTCTCTTGCTCT 200
Col I TTGACCCTAACCAAGGATGC CACCCCTTCTGCGTTGTATT 197
Col III AGAGGATGGCTGCACTAAACAC TTGGTCACTTTCACTGGTTGAC 201
ALP GTCACAGCCAGTCCCTCAAC TATTCCAAACAGGGGAGTCG 210
Aggrecan CTTGGGCAGAAGAAAGATCG GTAGGTGTTGGGGTCTGTGC 153
Biglycan GGAGGCCCAGAATCCTATCC ACTCCCTCCTGCTGGGTACA 236
Decorin TAGCATCACCGTTGTGGAAA CCGGACAGGGTTGCTATAAA 241
Elastin GCTGCTTTGGGAAATCTTGT TTCCTTGTCCTGTGGGTTTT 198
OCN AGCTCAACCCCAATTGTGAC AGCTGTGCCGTCCATACTTT 190
Six 1 TTTAATGGGGGTTTTGGTGA AATACCAGGTTGCCAGGTTG 204
hBMP-12
(120bp)
GAPDH
(200bp)
Vehicle BMP-12
(a)
100μm
(b)
Figure 3: (a) An example of a speciﬁc PCR product for hBMP-12,
which was observed in the BMP-12 group at 2 weeks (a product
for hBMP-2 is not shown). The atelocollagen group carrying the
vehicle vector did not express hBMP-12 at all. (b) Evidence that the
transgene system was successful. This GFP signal was produced in
a specimen treated only with the vehicle pEGFP-N1 plasmid vector.
TheimagewascapturedbyCLSMafterextractingthespecimentwo
weeks after the initial operation.
weeks after implantation. This expression had attenuated
by 4 and 8 weeks (data not shown). Images from the CLSM
indicated successful uptake and expression of the vehicle
(Figure 3(b)).
3.2. Histological Analysis. Two weeks after operation, the two
BMP groups clearly diﬀered from each other (Figure 4(a)).
While ﬁbrogenesis was observed in rats implanted with
BMP-12, osteogenesis was prominent in BMP-2 rats. In the
sham group, almost all of the atelocollagen remained where
ithadinitiallybeendeposited.Ontheotherhand,thecontrol
grouphadexperiencedboneregeneration.Formationofnew
collagen ﬁbers occurred at a higher rate in the BMP-12
group than in any other treatment group. After 4 weeks, the
atelocollagen framework remained in all groups, especially
the sham group; at this time, the control group showed
new bone formation in the bone defect. On the other
hand, dense collagen ﬁbers were observed in the BMP-12
group (Figure 4(b)); these were replaced with bone growth
by the end of the experiment at 8 weeks. Complete bone
replacement, including invasion of bone marrow cells, was
ﬁnally observed in all groups by the end of the study
(Figure 4(c)).
3.3. Gene Expression. As early as 2 weeks after the operation,
expression of connective tissue genes (speciﬁcally, collagen
III and decorin) was signiﬁcantly higher in the BMP groups
than in the sham group (Figure 5). Expression of genes
associated with connective tissues (collagen I and III), bone
and cartilage (ALP, biglycan), and tendons (Six1) were
particularly highly upregulated in the BMP-2 group. We
noticed two additional interesting patterns: ﬁrst, expression
of decorin did not increase among members of the BMP-2
group; second, ALP gene expression was not elevated in the
BMP-12 group despite its prominent increase in the BMP-2
group. In other words, the BMP associated with bone growth
(BMP-2) did not increase expression of connective tissue
genes, while the BMP associated with connective tissues
(BMP-12) did not increase expression of bone/cartilage
genes.
After 4 weeks, the BMP-12 group expressed signiﬁcantly
higher levels of mRNAs associated with bone repair activity
than the sham group. These included biglycan, elastin, and,
especially, Six1.
At the ﬁnal time point of 8 weeks, ALP gene expression
was higher in both BMP groups than in the control group,
and all three of these groups had higher ALP gene expression
than the sham group. Notably, osteocalcin gene expression
wassigniﬁcantlyhigherintheshamgroupthanintheBMP-2
group.Thiswassurprisingsinceosteocalcinisresponsiblefor
bone/cartilage activity, which should not have been directly
stimulated by the sham treatment. Other gene expression
relatedtotendon/ligamentregenerationinbothBMPgroups
had decreased by the end of the study.
4. Discussion
Most BMP family members induce the diﬀerentiation of
mesenchymal cells into osteoblastic cells or cartilage cells.
Both in vitro and in vivo studies, however, have indicatedJournal of Tissue Engineering 5
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Figure 4: Histological images of defects treated with each of the diﬀerent implants. Longitudinal sections were prepared at (a) 2 weeks, (b) 4
weeks, and (c) 8 weeks after the operation. The sections were stained with Masson’s trichrome. The left-side panels show low-magniﬁcation
images, and the right-side panels show high-power images. Bars in the left and the right panels show 300 μm and 100μm, respectively. A:
atelocollagen, NB: newly-formed bone, NF: newly-formed ﬁber.6 Journal of Tissue Engineering
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Figure 5: Gene expression in three of the study treatments at each of the time steps. Solid lines indicate the BMP-12 group; dashed lines
indicate the BMP-2 group; long dashed/double-dot lines indicate the atelocollagen group. Data are expressed as fold change relative to the
sham; statistical signiﬁcance was deﬁned as any P<. 05(n = 6). (a) BMP-2 versus sham; (b) BMP-2 versus BMP-12; (c) BMP-2 versus
control; (d) BMP-12 versus sham; (e) BMP-12 versus control; (f) sham versus control.
that BMP-12 is functionally diﬀerent from other members of
the BMP family [5, 8, 9]; in that it stimulates proliferation of
tendon ﬁbroblasts [7, 10] and induces tendon and ligament
formation [5]. Previously, its eﬀects on bone and cartilage
formation have only rarely been reported. Here, we have
examined the possibility that BMP-12 might play a role in
healing injured bone, as well as connective tissues. If this
is the case, BMP-12 could be a valuable new part of bone
regeneration treatments, particularly among orthopedic and
dental injuries.
Each of the four treatment groups in our study showed
diﬀerent histological appearances at each time point. Gen-
erally, changes in bone-speciﬁc gene expressions serve as
a good indication of the bone formation process. ALP
is a marker that intimately associates with early-phase
osteoblastic diﬀerentiation. Both our histological and RT-
PCR results indicated that ALP expression peaked in the
BMP-2 group 2 weeks after plasmid insertion. However, ALP
geneexpressionintheBMP-12groupwasfairlyconstantover
the experimental period. These results are not surprising,
given that ALP is associated with bone and cartilage,
structures that are known to be impacted by BMP-2.
At the 2-week time point, the BMP-2 group experienced
a strong peak of collagen I similar to the peak seen in
ALP. This suggested the initiation of osteogenesis, leading
to newly-formed bone by the ﬁnal time point. On the other
hand, gene expression of ALP and collagen I in the BMP-
12 group maintained low levels and showed no peak during
the study period. This might have resulted in only a partial
replacement of the cavity with new bone by 8 weeks. These
ﬁndings are similar to those from earlier studies, where ALP
gene expression and activity were not altered by BMP-12
gene transfer in C3H10T1/2 or tendon cells [8, 9], and,
furthermore, where subcutaneous implantation of BMP-12
induced tendon and ligament generation, rather than bone
formation [5].
Recent in vivo and in vitro works showed that Achilles
tendons produce more collage III after they have rupturedJournal of Tissue Engineering 7
than when they are healthy [20, 21]. This suggests that
collagen III has an important role in the healing process of
tendons and/or ligaments, perhaps as a provisional matrix
[22]. Collagen III is also essential for normal collagen I
ﬁbrillogenesis [23, 24]. We observed high levels of collagen
III gene expression at the 2-week mark in both BMP
groups. This provides additional evidence that BMP-12 plays
a vital role in inducing collagen III formation for early
tendon/ligament development. The prominent expressions
of both ALP and collagen I genes in the BMP-2 group,
however, likely masked the function of Collagen III essential
for induction of tendon/ligament growth. It is this masking
processthatmayberesponsibleformakingBMP-2akeypart
of the osteogenesis process, instead.
Decorin accounts for approximately 90% of the total
proteoglycans in fresh ligaments. The other 10% comprises
species such as biglycan, versican, and aggrecan [25]. Both
decorin and biglycan belong to the small leucine-rich
proteoglycanfamily;membersofwhicharefoundintendons
and ligaments and have been implicated as regulating agents
of ﬁbrillogenesis [25–28]. Biglycan is functionally related to
BMPs and seems more likely than decorin to be related to
osteogenesis rather than ﬁbrillogenesis [29–31]. Indeed, we
found that decorin levels were comparable between BMP-2
and BMP-12 groups at 2 weeks, and, furthermore, that
decorin levels had decreased in the BMP-12 group by 4
weeks. Furthermore, we observed higher levels of biglycan
gene expression in BMP-2 than in BMP-12 at two weeks,
which is consistent with the hypothesis that biglycan is
important for osteogenesis. However, we did also ﬁnd that
gene expression of biglycan in the BMP-12 group increased
at 4 weeks, suggesting that BMP-12 may play a role not
only in early tendon/ligament formation, but also following
osteogenesis.
Observation of the control group indicated that the bone
defect could heal naturally after 8 weeks. We anticipated
that the atelocollagen scaﬀolding used in the BMP and
sham treatments of this study might delay bone healing,
since previous clinical trials have shown that it degrades
very slowly in the body [17–19]. However, the exogenous
BMP-2 and BMP-12, contrarily, brought about the newly
formed bone by 2 to 8 weeks, which might be supported
by the osteocalcin gene expression proﬁle identical between
the BMP-12 and BMP-2 groups. Samples collected 4 weeks
after the operation indicated that bone formation in the
BMP-2groupoccurredeveninthepresenceoftheremaining
atelocollagen; this may be due to the overriding eﬀects of
the BMP-2 gene activity. By 8 weeks after the operation,
all groups (even the BMP-12 group) were able to almost
completely heal the bony defect.
In addition to diﬀerences in bone regeneration, the
four treatment groups exhibited diﬀerences in the healing
process, particularly in the amount and location of newly-
formed, collagen-like tissue. Both BMP groups and the sham
group were exposed to atelocollagen-containing treatments.
However, only the BMP-12 group obtained dense collagen-
like tissue prior to osteogenesis (between 2 and 4 weeks after
the operation). On the other hand, the other two groups
maintained more or less randomly scattered pieces of the
implanted atelocollagen, throughout the bone regeneration
process, until the end of the study. Thus, the ﬁbrous tissue
observed in the BMP-12 group was most likely generated by
BMP-12 activity.
Other researchers followed a subcutaneous application
of atelocollagen in a rhesus monkey for up to 26 weeks
[32]. Their work indicates that, in addition to the uses
of atelocollagen detailed in the current study, this delivery
system might act as a good space keeper for generating
tissueswhenimplantedsubcutaneously.Indeed,ourresearch
demonstrated a discrepancy in the roles between BMP-12
and BMP-2 when used with materials such as atelocol-
lagen. Our study was not designed to examine whether
the regeneration of an injured tendon/ligament adjacent to
the bone defect was healed or strengthened by BMP-12.
Future work should aim to understand whether BMP-12
synchronizes the activity of genes linked to bones/cartilage
and tendons/ligaments during the healing process.
The present study has demonstrated that BMP-12
gene transfer into a rat femoral bone defect induced
tendon/ligament-like tissue formation with increased gene
expression of tendon/ligament-related genes until 4 weeks
after the operation. Further, we have also demonstrated that
thesetissueswereeventuallyreplacedwithbone-liketissueby
8 weeks after the operation. However, additional studies are
required to further explore the mechanism by which BMP12
initiated the replacement of tendon/ligament-like tissue with
bony tissue.
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